X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response

Oncotarget

Volumn 7, Issue 20, 2016, Pages 29648-29663

  Zhao, Zhixin ^a   Zhu, Jianming ^a   Quan, Haitian ^a   Wang, Guimin ^a   Li, Bo ^a   Zhu, Weiliang ^a   Xie, Chengying ^a   Lou, Liguang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Celastrol; Heat shock response; HSF 1; HSP90; X66

Indexed keywords

4 [2 [(1H INDOL 3 YL)METHYLENE]HYDRAZINYL] N (4 BROMOPHENYL) 6 (3,5 DIMETHYL 1H PYRAZOL 1 YL) 1,3,5 TRIAZIN 2 AMINE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CELASTROL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELDANAMYCIN; HEAT SHOCK PROTEIN 72; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; LUMINESPIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HYDRAZONE DERIVATIVE; TRIAZINE DERIVATIVE; X66 COMPOUND;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL LINE; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TUMOR LEVEL; FEMALE; HEAT SHOCK RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; SINGLE DRUG DOSE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL NEOPLASM; HUMAN; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYDRAZONES; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; TRIAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84969799989     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8818     Document Type: Article

References (51)

1. Li J, Soroka J and Buchner J. The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones. Biochimica et biophysica acta. 2012; 1823:624-635.
2. Wandinger SK, Richter K and Buchner J. The Hsp90 chaperone machinery. The Journal of biological chemistry. 2008; 283:18473-18477.
3. Alarcon SV, Mollapour M, Lee MJ, Tsutsumi S, Lee S, Kim YS, Prince T, Apolo AB, Giaccone G, Xu W, Neckers LM and Trepel JB. Tumor-intrinsic and tumor-extrinsic factors impacting hsp90-targeted therapy. Current molecular medicine. 2012; 12:1125-1141.
4. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW and Pearl LH. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell. 1997; 90:65-75.
5. Whitesell L, Mimnaugh EG, De Costa B, Myers CE and Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proceedings of the National Academy of Sciences of the United States of America. 1994; 91:8324-8328.
6. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU and Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell. 1997; 89:239-250.
7. Sepp-Lorenzino L, Ma Z, Lebwohl DE, Vinitsky A and Rosen N. Herbimycin A induces the 20 S proteasomeand ubiquitin-dependent degradation of receptor tyrosine kinases. The Journal of biological chemistry. 1995; 270:16580-16587.
8. Mimnaugh EG, Chavany C and Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. The Journal of biological chemistry. 1996; 271:22796-22801.
9. Hostein I, Robertson D, DiStefano F, Workman P and Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer research. 2001; 61:4003-4009.
10. Garon EB MT, Barlesi F, Gandhi L, Sequist LV, Kim SW, et al. Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2012; 30.
11. Socinski MA KM, Goldman J, Paschold E, Horn L, Lufkin J, et al. (2011). An Open-Label Phase Ii Study of the Hsp90 Inhibitor Ganetespib (Sta-9090) in Patients with Advanced Non-Small Cell Lung Cancer (Nsclc). J Thorac Oncol, pp. S467-S468.
12. Zou J, Guo Y, Guettouche T, Smith DF and Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stresssensitive complex with HSF1. Cell. 1998; 94:471-480.
13. Ali A, Bharadwaj S, O'Carroll R and Ovsenek N. HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes. Molecular and cellular biology. 1998; 18:4949-4960.
14. Sarge KD, Murphy SP and Morimoto RI. Activation of heat shock gene transcription by heat shock factor 1 involves oligomerization, acquisition of DNA-binding activity, and nuclear localization and can occur in the absence of stress. Molecular and cellular biology. 1993; 13:1392-1407.
15. Baler R, Dahl G and Voellmy R. Activation of human heat shock genes is accompanied by oligomerization, modification, and rapid translocation of heat shock transcription factor HSF1. Molecular and cellular biology. 1993; 13:2486-2496.
16. Powers MV, Clarke PA and Workman P. Death by chaperone: HSP90, HSP70 or both? Cell cycle. 2009; 8:518-526.
17. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E and Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell cycle. 2006; 5:2592-2601.
18. Powers MV, Clarke PA and Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer cell. 2008; 14:250-262.
19. McCollum AK, Teneyck CJ, Sauer BM, Toft DO and Erlichman C. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldana mycin through a glutathione-mediated mechanism. Cancer research. 2006; 66:10967-10975.
20. Massey AJ, Williamson DS, Browne H, Murray JB, Dokurno P, Shaw T, Macias AT, Daniels Z, Geoffroy S, Dopson M, Lavan P, Matassova N, Francis GL, Graham CJ, Parsons R, Wang Y, et al. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer chemotherapy and pharmacology. 2010; 66:535-545.
21. Mendillo ML, Santagata S, Koeva M, Bell GW, Hu R, Tamimi RM, Fraenkel E, Ince TA, Whitesell L and Lindquist S. HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell. 2012; 150:549-562.
22. Chen Y, Chen J, Loo A, Jaeger S, Bagdasarian L, Yu J, Chung F, Korn J, Ruddy D, Guo R, McLaughlin ME, Feng F, Zhu P, Stegmeier F, Pagliarini R, Porter D, et al. Targeting HSF1 sensitizes cancer cells to HSP90 inhibition. Oncotarget. 2013; 4:816-829. doi: 10.18632/oncotarget.991.
23. Peterson LB and Blagg BS. To fold or not to fold: modulation and consequences of Hsp90 inhibition. Future medicinal chemistry. 2009; 1:267-283.
24. Neckers L and Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clinical cancer research. 2012; 18:64-76.
25. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall F, Aherne W, Rowlands M, Hayes A, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer research. 2008; 68:2850-2860.
26. Akerfelt M, Morimoto RI and Sistonen L. Heat shock factors: integrators of cell stress, development and lifespan. Nature reviews Molecular cell biology. 2010; 11:545-555.
27. Guettouche T, Boellmann F, Lane WS and Voellmy R. Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress. BMC biochemistry. 2005; 6:4.
28. Westerheide SD and Morimoto RI. Heat shock response modulators as therapeutic tools for diseases of protein conformation. The Journal of biological chemistry. 2005; 280:33097-33100.
29. Suda A, Kawasaki K, Komiyama S, Isshiki Y, Yoon DO, Kim SJ, Na YJ, Hasegawa K, Fukami TA, Sato S, Miura T, Ono N, Yamazaki T, et al. Design and synthesis of 2-amino-6-(1H, 3H-benzo[de]isochromen -6-yl)-1,3,5-triazines as novel Hsp90 inhibitors. Bioorganic & medicinal chemistry. 2014; 22:892-905.
30. Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL and Erlichman C. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clinical cancer research. 2006; 12: 6087-6093.
31. P. W. Piper SHM. Mechanisms of Resistance to Hsp90 Inhibitor Drugs: A Complex Mosaic Emerges. Pharmaceuticals. 2011; 4:1400-1422.
32. Home T, Jensen RA and Rao R. Heat shock factor 1 in protein homeostasis and oncogenic signal integration. Cancer research. 2015; 75:907-912.
33. Ganguly S, Home T, Yacoub A, Kambhampati S, Shi H, Dandawate P, Padhye S, Saluja AK, McGuirk J and Rao R. Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. Oncotarget. 2015; 6:31767-79. doi: 10.18632/oncotarget.5167.
34. Wang Y and McAlpine SR. C-terminal heat shock protein 90 modulators produce desirable oncogenic properties. Organic & biomolecular chemistry. 2015; 13:4627-4631.
35. Lee SC, Min HY, Choi H, Bae SY, Park KH, Hyun SY, Lee HJ, Moon J, Park SH, Kim JY, An H, Park SJ, Seo JH, et al. Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity. Cancer research. 2016; 76:686-699.
36. Eskew JD, Sadikot T, Morales P, Duren A, Dunwiddie I, Swink M, Zhang X, Hembruff S, Donnelly A, Rajewski RA, Blagg BS, Manjarrez JR, Matts RL, Holzbeierlein JM and Vielhauer GA. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC cancer. 2011; 11:468.
37. Ardi VC, Alexander LD, Johnson VA and McAlpine SR. Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins. ACS chemical biology. 2011; 6:1357-1366.
38. Kunicki JB, Petersen MN, Alexander LD, Ardi VC, McConnell JR and McAlpine SR. Synthesis and evaluation of biotinylated sansalvamide A analogs and their modulation of Hsp90. Bioorganic & medicinal chemistry letters. 2011; 21:4716-4719.
39. Wang Y and McAlpine SR. Heat-shock protein 90 inhibitors: will they ever succeed as chemotherapeutics? Future medicinal chemistry. 2015; 7:87-90.
40. McConnell JR, Alexander LA and McAlpine SR. A heat shock protein 90 inhibitor that modulates the immunophilins and regulates hormone receptors without inducing the heat shock response. Bioorganic & medicinal chemistry letters. 2014; 24:661-666.
41. Wang Y and McAlpine SR. N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes. Chemical communications. 2015; 51:1410-1413.
42. McCollum AK, Lukasiewicz KB, Teneyck CJ, Lingle WL, Toft DO and Erlichman C. Cisplatin abrogates the geldanamycin-induced heat shock response. Molecular cancer therapeutics. 2008; 7:3256-3264.
43. Bagatell R, Paine-Murrieta GD, Taylor CW, Pulcini EJ, Akinaga S, Benjamin IJ and Whitesell L. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clinical cancer research. 2000; 6:3312-3318.
44. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN, Clardy J, Hahn WC, et al. Gene expression signaturebased chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer cell. 2006; 10:321-330.
45. Yang H, Chen D, Cui QC, Yuan X and Dou QP. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer research. 2006; 66:4758-4765.
46. Vallee F, Carrez C, Pilorge F, Dupuy A, Parent A, Bertin L, Thompson F, Ferrari P, Fassy F, Lamberton A, Thomas A, Arrebola R, Guerif S, et al. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone. Journal of medicinal chemistry. 2011; 54:7206-7219.
47. Kim J, Felts S, Llauger L, He H, Huezo H, Rosen N and Chiosis G. Development of a fluorescence polarization assay for the molecular chaperone Hsp90. Journal of biomolecular screening. 2004; 9:375-381.
48. Wang Q, Quan H, Zhao J, Xie C, Wang L and Lou L. RON confers lapatinib resistance in HER2-positive breast cancer cells. Cancer letters. 2013; 340:43-50.
49. Zhao J, Quan H, Xu Y, Kong X, Jin L and Lou L. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/ KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer science. 2014; 105:117-125.
50. DWR JS. (2006). Molecular Cloning. (New york: Cold Spring Harbor Laboratory Press).
51. Mercier PA, Winegarden NA and Westwood JT. Human heat shock factor 1 is predominantly a nuclear protein before and after heat stress. Journal of cell science. 1999; 112:2765-2774.